<DOC>
	<DOCNO>NCT00348738</DOCNO>
	<brief_summary>The purpose study determine whether increase blood haemoglobin level substitution erythropoietin radiotherapy treatment cervix cancer patient result improvement disease specific survival , tumor response local control .</brief_summary>
	<brief_title>Impact Erythropoietin Administration During Definitive Cervix Cancer Radiotherapy Treatment Outcome</brief_title>
	<detailed_description>Definitive radiotherapy treatment choice patient locally advanced cervix cancer . Low pre-therapeutic value intratumoral pO2 associate significantly worse therapeutic outcome blood hemoglobin level correlate positively intratumoral pO2 . Successful augmentation hemoglobin level way transfusion lead improvement therapeutic result . Therefore , pre-therapeutic transfusion therapy carry routinely number hospital ; however therapy due cost risk limit patient initial hemoglobin level &lt; 10 g/dl . To avoid transfusion increase patient wellbeing , efficacy tolerability erythropoietin test , administered increase lower hemoglobin level tumor patient . The question , whether possible , regularly raise blood hemoglobin level patient carcinoma cervix administer erythropoietin . If normal ( &gt; 12 g/dl ) rather upper-normal ( &gt; 14 g/dl ) hemoglobin level reach , tumor oxygenation thus also response radiation could positively influence . The objective study improve response control rate well disease free survival rate female patient primary carcinoma cervix within scope curative radiation therapy . The test hypothesis administer erythropoietin hemoglobin level increase increase response tumor radiation therapy improve . Comparison ( ) : A prospective , randomize , multi-centric group female patient treat Erythropoietin compare parallel stratify control group receive treatment .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>histologically proven cervix cancer ( FIGO stage IIVA ) Age 1980 year initial blood level hemoglobin &lt; = 14 g/dl patient give inform consent KarnofskyIndex &lt; 50 % know intolerance erythropoietin FIGO stage IVB blood transfusion within last four week neoadjuvant chemotherapy previous radiation therapy abdomen</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>radiotherapy</keyword>
	<keyword>clinical trial</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>cervix cancer</keyword>
	<keyword>Phase III</keyword>
	<keyword>2 Arms</keyword>
</DOC>